Completion of Facility Enables Initiation of Phase 3 Clinical Trial of Nepafenac in Patients Undergoing Cataract Surgery AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") ...
Punctal plugs effectively improve symptoms of dry eye disease, enhancing tear breakup time, tear production, and Ocular Surface Disease Index. The review included 17 studies with a high retention rate ...
AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") announced that it has completed and now occupies a facility dedicated to manufacturing all products formulated in Mati's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results